Skip to main content

Table 1 Characteristics and summary data of the included studies

From: Is rs759853 polymorphism in promoter of aldose reductase gene a risk factor for diabetic nephropathy? A meta-analysis

Studies (first author publication years) Racial decent (country) Disease diagnostic standard Study design Type of diabetes Clinical characteristics (control/case) HWE P value Sample size (control/case) Genotype distribution (control/case) Frequency of allele T (%) (control/case)
Age (year) Duration of diabetes (year) Male (%) T/T T/C C/C
So et al. [12] Asians (China) Diabetes: not mentioned; DN: GFR < 60 ml/min/1.72 m2 Prospective design Type 2 -/- 7.5/8.0 -/- >0.05 866/208 44/13 269/76 553/119 18.6/22.2
Wolford et al. [13] Caucasians (America) Diabetes: not mentioned; DN: ACR ≥ 300 mg/g Case-control design Type 2 55.9/58.0 20.4/20.7 43.9/31.5 >0.05 105/103 5/1 26/32 74/70 17.1/16.5
Gosek et al. [14] Caucasians (Poland) Diabetes: NDDG (1979); DN: ACR ≥ 1.9 mg/mmol (men) or ≥2.8 mg/mmol (women) Prospective design Type 2 -/- 14.0/- -/- >0.05 162/282 20/40 85/145 57/97 38.6/39.9
Sivenius et al. [15] Caucasians (Finland) Diabetes: WHO (1980); DN: UAE > 30 mg/24 h Prospective design Type 2 -/- 10.0/10.0 -/- >0.05 68/17 1/2 17/7 50/8 14.6/32.4
Makiishi et al. [16] Asians (Japan) Diabetes: WHO (1999); DN: AER ≥ 20 μg/min Case-control design Type 2 65.0/64.0 19.0/17.0 46.5/55.6 >0.05 228/230 3/13 66/63 159/144 15.8/20.2
Wang et al. [17] Asians (China) Diabetes: not mentioned; DN: AER ≥ 20 μg/min Case-control design Type 2 52.3/60.8 4.2/8.1 38.9/46.1 >0.05 458/280 26/15 130/96 302/169 19.9/22.5
Fanelli et al. [18] Caucasians (France) Diabetes: not mentioned; DN: not mentioned Prospective design Type 1 -/- 14.6/22.2 -/- >0.05 157/335 33/61 69/161 55/113 44.8/42.2
Neamat-Allah et al. [19] Caucasians (Ireland) Diabetes: not mentioned DN: UAE > 300 mg/24 h Case-control design Type 1 -/- -/- -/- >0.05 102/107 7/22 31/44 64/41 22.1/40.0
Neamat-Allah et al. [19] Caucasians (England) Diabetes: not mentioned DN: UAE > 300 mg/24 h Case-control design Type 1 -/- 29.0/26.3 48.9/61.2 >0.05 85/77 12/19 30/39 43/19 31.8/50.0
Neamat-Allah et al. [19] Caucasians (England) Diabetes: not mentioned DN: UAE > 300 mg/24 h Case-control design Type 2 -/- 8.9/12.6 54.4/65.9 >0.05 146/85 33/20 48/45 65/20 39.0/50.0
Neamat-Allah et al. [19] Pima Indians (America) Diabetes: not mentioned DN: UAE > 300 mg/24 h Case-control design Type 2 -/- -/- -/- >0.05 154/181 4/7 40/61 110/113 15.6/20.7
Moczulski et al. [20] Caucasians (America) Diabetes: not mentioned DN: ACR ≥ 17 μg /mg (men) or ≥25 μg /mg (women) Case-control design Type 1 35.5/36.3 23.3/24.9 -/- >0.05 193/221 22/35 83/112 88/74 32.9/41.2
  1. Abbreviations: ACR albumin-creatinine ratio, AER albumin excretion rate, DN diabetic nephropathy, GFR glomerular filtration rate, HWE Hardy-Weinberg equilibrium, NDDG National Diabetes Data Group, UAE urinary albumin excretion.